What You Should Know:
– PathAI, a provider of AI and digital pathology solutions, and Moffitt Cancer Center, a top cancer hospital, have announced a multi-year strategic collaboration to deploy PathAI’s digital pathology platform, AISight® Dx, across Moffitt’s pathology programs. The partnership aims to transform cancer detection and research through the use of AI.
AISight® Dx: Cloud-Native Digital Pathology
AISight® Dx is a cloud-native digital pathology image management system that supports both laboratory workflow and translational research. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, which enhances speed and accuracy while driving scalable pathology operational efficiencies.
Integrating AI for Enhanced Diagnosis and Research
The collaboration will equip Moffitt’s pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock new insights from pathology data. The partnership also establishes a framework for joint research programs, the collation of real-world multimodal data, and initiatives to support clinical trials and biopharma collaborations. PathAI and Moffitt will also co-develop next-generation AI-based diagnostics to enhance precision medicine.
“We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,” said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. “By deploying AISight® Dx and building this strategic partnership, we’re equipping Moffitt’s pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.”
